2024
Potential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence
Manhapra A, Rosenheck R, Becker W. Potential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence. 2024, 148-164. DOI: 10.1093/9780197675250.003.0009.Peer-Reviewed Original ResearchLong-term opioid therapyKappa-opioid receptorsChronic painOpioid receptorsKappa-opioid receptor antagonismManagement of comorbid depressionTherapeutic agentsMOR agonismOpioid therapyOpioid taperAntidepressant effectsWorsening painOpioid dependenceSafety profileAgonist actionPoor outcomeClinical trialsAssociated with worsening depressionPainEtiological driversBuprenorphineReceptor affinityComorbid depressionOpioidReceptors
2023
Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration
Rosenheck R, Anand S, Kurtz S, Hau C, Smedberg D, Pontzer J, Ferguson R, Davis C. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration. Trials 2023, 24: 85. PMID: 36747254, PMCID: PMC9900548, DOI: 10.1186/s13063-023-07094-6.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsLAI risperidoneClinical practiceLAI second-generation antipsychoticsInjectable second-generation antipsychoticsPractical clinical trialsVeterans Health AdministrationClinical trial resultsStudy publicationDiagnosis of schizophreniaNational administrative dataLongitudinal observational analysisLAI paliperidoneOral antipsychoticsReal-world practiceInjectable risperidoneTrial findingsClinical trialsLAI treatmentRisperidoneSchizoaffective disorderHealth AdministrationCooperative StudyAntipsychoticsDrug expendituresImpact of multi-site clinical trial results on clinical practice: Use of risperidone to treat PTSD nationally in the veterans health administration
Rosenheck R, Kurtz S, Anand S, Hau C, Smedberg D, Sicilia R, Pontzer J, Ferguson R. Impact of multi-site clinical trial results on clinical practice: Use of risperidone to treat PTSD nationally in the veterans health administration. Psychiatry Research 2023, 321: 115071. PMID: 36720177, DOI: 10.1016/j.psychres.2023.115071.Peer-Reviewed Original ResearchConceptsClinical practiceNational VHA administrative dataOral second-generation antipsychoticsUse of risperidoneVHA administrative dataSecond-generation antipsychoticsMulti-site clinical trialVeterans Health AdministrationClinical trialsEffectiveness trialHealth AdministrationRisperidoneCooperative StudyYear of publicationAdministrative dataPTSDTrialsYearsAntipsychoticsStudy resultsAdministrationGender differences in outcomes of early intervention services for first episode psychosis
Hong S, Bennett D, Rosenheck R. Gender differences in outcomes of early intervention services for first episode psychosis. Early Intervention In Psychiatry 2023, 17: 715-723. PMID: 36623822, PMCID: PMC10329725, DOI: 10.1111/eip.13367.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisEarly intervention servicesClinical trialsEpisode psychosisInitial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) studyEarly interventionIntervention servicesRandomized clinical trialsComorbid substance useUS clinical trialsSignificant gender differencesNegative Syndrome ScaleBaseline gender differencesGender differencesSchizophrenia spectrum disordersAntipsychotic exposureUsual careBaseline characteristicsMood symptomsDepression subscalePsychotic disordersMasked evaluatorsSchizoaffective disorderSyndrome ScaleSecondary analysis
2003
IMPACT OF PUBLIC SUPPORT PAYMENTS, INTENSIVE PSYCHIATRIC COMMUNITY CARE, AND PROGRAM FIDELITY ON EMPLOYMENT OUTCOMES FOR PEOPLE WITH SEVERE MENTAL ILLNESS
RESNICK S, NEALE M, ROSENHECK R. IMPACT OF PUBLIC SUPPORT PAYMENTS, INTENSIVE PSYCHIATRIC COMMUNITY CARE, AND PROGRAM FIDELITY ON EMPLOYMENT OUTCOMES FOR PEOPLE WITH SEVERE MENTAL ILLNESS. The Journal Of Nervous And Mental Disease 2003, 191: 139. DOI: 10.1097/00005053-200303000-00001.Peer-Reviewed Original ResearchIntensive psychiatric community careSevere mental illnessPublic support paymentsMental illnessPsychiatric community careStudy entryControl subjectsClinical trialsCommunity careMultivariate analysisLower likelihoodIllnessProgram fidelityCareOutcomesSignificant interactionEmployment outcomesParticipantsPatientsFidelity of implementationYearsPsychiatricTrials
2000
Quality of Life in Schizophrenia: A Comparison of Instruments
Cramer J, Rosenheck R, Xu W, Thomas J, Henderson W, Schizophrenia D. Quality of Life in Schizophrenia: A Comparison of Instruments. Schizophrenia Bulletin 2000, 26: 659-666. PMID: 10993404, DOI: 10.1093/oxfordjournals.schbul.a033484.Peer-Reviewed Original ResearchConceptsHealth-related qualityClinical trialsTreatment effectsPatient-reported qualityLife InterviewGlobal clinical ratingsLife ScaleQuality of lifePatient responseModerate-high correlationClinical ratingsFunction scaleSymptom severitySchizophreniaStructured interviewsTrialsComparison of instrumentsRaters' assessmentsClozapineHaloperidolInpatientsLifeMultiple measuresSeverity
1998
Predictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis